K Health vs Ro
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
K Health
Best for users who want general primary care with GLP-1 prescribing as one available option, not a single-condition weight-loss funnelStarting at $300/mo
Ro
Best for broadest GLP-1 formulary including Foundayo on day-one of launchStarting at $149/mo
Side-by-Side Comparison
| Feature | K Health | Ro |
|---|---|---|
| Overall Score | 6.6/10 | ✓7.9/10 |
| Starting Price | $300/mo | ✓$149/mo |
| Editorial Rating | 3.3 ★ /5 | ✓4 ★ /5 |
| Features | 4 features | ✓7 features |
| States Available | 0 | 0 |
| Compounded | — | — |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
K Health
Pros
- ✓Established US telehealth with health-system integrations (Cedars-Sinai, Hartford HealthCare, Hackensack Meridian)
- ✓AI intake reduces upfront friction for users who don't want to sit through a long questionnaire before seeing a clinician
- ✓Primary-care relationship rather than a single-condition funnel — useful for users who want one provider managing multiple conditions
Cons
- ✗Not a GLP-1 specialty platform — weight management is ancillary to primary care, and GLP-1 prescribing is clinician-discretionary at the visit level
- ✗Pricing for GLP-1 specifically is not displayed publicly — needs direct confirmation from K Health support before placing readers
- ✗States served list and pharmacy partners are not publicly enumerated
Ro
Pros
- ✓Most comprehensive GLP-1 formulary in telehealth — compounded semaglutide, brand-name Wegovy, brand-name Zepbound, and the new oral Foundayo (orforglipron) all available on one platform
- ✓Among the first telehealth providers to launch Foundayo on day one of the Lilly partner rollout (April 9 2026)
- ✓Clinician-led plan selection — 'patients connect with a licensed provider and, if appropriate, determine which GLP-1 is the best option based on their insurance coverage, the cost, and their unique clinical needs and health goals'
- ✓Nationwide delivery network — Ro reports having served patients in 'nearly every single county in the United States, including 99% of primary care deserts'
- ✓Both cash-pay and insurance-eligible options under one roof
Cons
- ✗Foundayo on Ro requires a recurring membership in addition to the $149/mo cash drug price — total monthly cost is higher than the headline number
- ✗Specific Foundayo dose-tier pricing above the lowest dose not publicly disclosed in the launch announcement — needs intake to confirm
- ✗State availability and pharmacy partners not itemized publicly — requires signup intake to verify
- ✗Like all telehealth GLP-1 providers, Ro charges separately for the program (membership) and the medication; users sometimes confuse the bundled vs. unbundled pricing models
Our Verdict
Ro edges out K Health with a higher overall score of 7.9/10 and is particularly strong for broadest GLP-1 formulary including Foundayo on day-one of launch. K Health remains a solid alternative, especially if you're looking for users who want general primary care with GLP-1 prescribing as one available option, not a single-condition weight-loss funnel.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.